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Abstract
Effective therapy for Alzheimer’s disease (AD), up to this point, has been hampered by our inability to
diagnose the disease in its early stages, before the occurrence of significant neurodegeneration and
clinical symptoms. Because AD historically has been defined by neuropathologic criteria, treatment
strategies have been aimed at diminishing the pathologic end result of the disease process, namely
neurodegenerative changes associated with extracellular amyloid-beta-containing plaques, as well as
intracellularneurofibrillarytanglesofthehyper-phosphorylatedmicrotubuleprotein,tau.Whilethese
avenues continue to be pursued, results thus far have been disappointing. It is now understood that
oxidative stress plays a key role in the shared pathophysiology of neurodegenerative diseases and
aging. For experimental treatment of AD, the focus of research and development efforts is
increasingly shifting to target mechanisms of oxidative stress. Most recently, dimebon, whose
mechanism of action relates to improved mitochondrial function, has emerged as a promising
candidate for experimental treatment of AD.
Introduction and context
While Alzheimer’s disease (AD) has been defined largely
through molecular mechanisms of neuronal dysfunc-
tion, there is growing evidence indicating that oxidative
stress and reactive oxygen species (ROS) contribute to
dementia. Oxidative stress refers to cellular damage
mediated by toxic ROS, the formation of which is due to
an imbalance between ROS production and the capacity
for removing ROS. ROS normally are produced as part of
well-characterized metabolic pathways of oxidative
phosphorylation during cellular respiration. Free
radicals, generally unstable and highly reactive, are
removed by specific detoxifying enzymes. With age,
increased metabolic demand, and diseases (including
AD), there is increased oxidative insult, heightened
superoxide radical formation, and increased superoxide
dismutase levels which may cause H2O2 to diffuse
through the mitochondrial membrane to the cytoplasm.
Most free radicals are produced by mitochondria, and
mitochondrial abnormalities in AD have been associated
with deficiencies of the enzymes of the Krebs cycle,
which may either increase free-radical production or alter
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transition metals aberrantly accumulate in AD-suscep-
tible neurons [6], and increased cytoplasmic H2O2,i n
the presence of redox-active metals and amyloid-beta
(Ab), may cause localized increased ROS concentration
[7-9]. Increased ROS results in oxidation of lipids and
RNA.
Studies suggest that there are multiple mechanisms by
which oxidative stress may accumulate and create
dysfunctional neuronal responses in AD and that
development of the AD phenotype requires multiple
insults [10-12]. Ischemia, inflammation, and aging are
all pro-oxidant conditions. The brain, with its high
oxygen use and a consumption of approximately 10% of
cardiac output, depends on a number of cellular and
tissue-specific antioxidant mechanisms for removal of
the resultant by-product of ROS. When these mechan-
isms are ineffective or dysregulated, there is characteristic
cellular injury.
The blood-brain barrier (BBB), critical to normal
neuronal function (including synaptic transmission,
remodeling, angiogenesis, and neurogenesis [13]), is
also substantially compromised in a subpopulation of
AD patients [14]. This may be a consequence of
endothelial cell injury and dysfunction. One result may
be impaired Ab transport to and from the brain via the
receptor for advanced glycation endproducts (RAGE)
and transcytosis of Ab into the brain parenchyma, where
it binds to neurons and may enhance formation of toxic
ROS.
Current treatment options
The current drugs approved by the US Food and Drug
Administration (FDA) to treat AD are the acetyl-
cholinesterase (AChE) inhibitors, such as donepizil,
and the N-methyl-D-aspartate (NMDA) receptor antago-
nist, memantine. These drugs are aimed at symptomatic
improvement in cognitive ability and are marginally
effective [15,16]. The AChE inhibitors are designed to
enhance cholinergic neurotransmission by reducing
breakdown of acetylcholine (ACh) in the synaptic cleft.
The benefit of AChE inhibitors is thought to relate to the
role of ACh in memory and the prominent degeneration
of basal forebrain cholinergic neurons in AD [17].
Despite its limited clinical efficacy, AChE inhibition
has been successful for over 20 years as the best available
treatment strategy for AD. More recently, memantine has
been FDA-approved for treating AD. Memantine is the
first in a class of NMDA receptor antagonists that
influence neurotransmission to provide marginal
improvement in memory formation and cognitive
function in AD [18].
Other psychotropic medications are also used to treat AD
patients symptomatically. With moderate to advanced
AD, patients frequently become agitated or develop
psychotic symptoms such as paranoid ideation and
auditory hallucinations. These symptoms often are
improved with psychotropic medications, including
atypical antipsychotics [19,20] such as risperidone and
olanzapine, and typical antipsychotics such as haloper-
idol [19-21]. These antipsychotic medications, though
often helpful, unfortunately carry the risk of precipitating
cerebrovascular accidents in older people [22]. Similar to
the AChE inhibitors and NMDA receptor antagonists, the
antipsychotic agents do not retard progression of the
neurodegenerative process. Benzodiazepines sometimes
are used, particularly in the acute setting, to treat agitated
patients with AD and are also sometimes prescribed for
insomnia, as circadian rhythms are frequently disrupted
in AD. Although the benzodiazepines are sometimes
helpful due to their anxiolytic and sedating properties, it
is usually best to avoid using them because they can
exacerbate cognitive impairment [23,24].
Recent advances
Redox-active compounds
The advances in the molecular and pathogenetic
mechanisms that evolve into the final pathologic picture
of AD provide enormous insight into possible targets for
newer, and hopefully more effective, therapy. Extracts of
Ginkgo biloba show antioxidant properties with reduced
superoxide release in polymorphonuclear leukocytes
[25]. Ginkgo constituents may act as scavengers of free
radicals [26] and increase cholinergic transmission in the
brain by inhibiting AChE [27], both of which may be
beneficial in AD. However, clinical studies of Ginkgo
have not consistently yielded positive results.
A randomized placebo-controlled trial using anti-
oxidant therapies alpha-tocopherol, selegiline, and com-
bination therapy showed significant delays in time to
death, placement in a nursing home, development of
severe dementia, or a defined severity of impairment of
activities of daily living [28]. Antioxidants may ablate
cognitive decline [29,30], suggesting that these strate-
gies are beneficial in reducing the risk for developing
AD. On the other hand, the beneficial effects of alpha-
tocopherol and selegiline and other antioxidants have
not always been reproduced in clinical trials [31]. It is
possible that the oxidative stress pathophysiology in
AD is so severe that conventional antioxidants have
marginal or insufficient power to buffer against
pathophysiologic redox metabolism. At the present
time, antioxidant therapy is not recommended in AD,
although patients frequently are advised by physicians
to take over-the-counter antioxidant supplements, partly
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Iron chelation
Chelation therapy offers another strategy for reducing
oxidative stress. Formation of the toxic hydroxyl radical
from H2O2 requires electron donation from Cu
+ or Fe
2+,
the latter being much more prevalent in the labile pools of
cytosolic redox-active metals. In the context of AD, the Ab
peptide is considered a strong redox-active agent that is
capableofreducingtransitionmetalsinthecytoplasmand
allowing the conversion of molecular oxygen to H2O2
[9,32,33]. The metal ion dyshomeostasis in AD, with high
levels of redox-active metals (particularly iron) being
found in the affected areas of the brain, suggests chelation
as a reasonable form of therapy. The use of covalent
conjugation of nanoparticles with iron chelators [34] has
been proposed to help overcome the limitation to
chelation therapy imposed by BBB permeability. This
unique approach would enable transport of chelators and
chelator-metalcomplexesinbothdirectionsacrosstheBBB.
Non-redox-active compounds
Numerous other compounds under development for
experimental treatment of AD do not directly quench
ROS through redox activity but are known to have
downstream antioxidant effects. There is epidemiologic
evidence that homocysteine is an independent risk factor
for the development of dementia [35], with a plasma
level of greater than 14 mM causing a twofold increased
risk of AD. A number of studies, however, show that the
central nervous system (CNS) is acutely sensitive to
homocysteine, which is also an NMDA receptor agonist
that stimulates calcium influx and promotes glutamate
excitotoxicity, and causes oxidative stress and DNA
damage. With its redox-active thiol residues, homocys-
teine can also impair the antioxidant activities of
glutathione. In addition, with its ability to coordinate
copper, homocysteine can promote one-electron transfer
reactions with H2O2, resulting in the formation of the
toxic hydroxyl radical. Elevated plasma homocysteine
and low folate may be risk factors for the development of
dementia and AD, spurring controlled studies on the
efficacy of folate supplementation and reduction of
homocysteine levels on dementia and AD [36,37].
Other compounds that have antioxidant effects and that
have been tested for efficacy in treating cognitive decline
include estrogen replacement, which was shown not to
be effective in treating post-menopausal AD. In experi-
mental studies, leuprolide, a selective gonadotropin-
releasing hormone agonist that markedly reduces secre-
tion of the gonadotropins, luteinizing hormone, and
follicle-stimulating hormone, is thought to divert Ab
protein precursor and reduce brain amyloid and ROS
formation [38]. Luteinizing hormone is found to be
elevated in AD due to the negative feedback stimulation
by low gonadal steroid levels. In clinical studies, female
AD patients treated with leuprolide showed stabilization
of cognitive impairment and activities of daily living.
Leptin is a centrally acting hormone that controls AMP
kinase, maintains lipid levels, and regulates glycogen
synthase kinase 3, which modulates tau phosphoryla-
tion. Leptin has been shown in vitro and in vivo to reduce
extracellular Ab and neuronal tau phosphorylation as
well as improve cognitive performance of transgenic
mouse models of AD. In humans, weight loss preceding
the onset of AD dementia is inversely proportionate in
severity to leptin levels, suggesting that leptin deficiency
contributes to systemic and CNS abnormalities in AD
and that this hormone may be a novel therapeutic agent
in AD, with antioxidant effects through its modulation of
intracellular signaling cascades [39].
Insight into the role of metabolic agents, which are
influenced by underlying genetics, has emerged. There is
a significant increased risk of developing AD in people
who have the gene for apolipoprotein E4 (ApoE4), a
protein that helps carry circulating cholesterol. A specific
fragment formed rapidly from ApoE4 plays a role in
oxidative stress by adversely affecting mitochondrial
function. It is thought also that poor glucose use and
insulin resistance, as seen in type 2 diabetes mellitus,
play a role in AD [40,41]. Preliminary results with the
oral hypoglycemic agent rosiglitazone in patients with
mild to moderate AD show that patients who do not
carry the ApoE4 gene show improvement whereas
patients with ApoE4 do not respond [42].
We are cautiously optimistic about the potential
therapeutic value of dimebon, a new candidate ther-
apeutic agent for AD. Dimebon has been shown to
inhibit degeneration of neurons and works through a
novel mechanism of action, improving mitochondrial
function. In a phase II randomized double-blind
placebo-controlled trial with mild to moderate AD,
dimebon-treated patients showed statistically significant
improvement in cognition, activities of daily living,
behavior, and overall function [43]. It was found to have
a positive impact on caregiver stress, reducing the
amount of time they needed to spend assisting patients.
It also showed a favorable side-effect profile. Larger scale
clinical trials of dimebon are clearly warranted.
Implications for clinical practice
While cholinesterase inhibitor and NMDA receptor
antagonists such as memantine, alone or in
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AD along with the promotion of proper nutrition and
occupational health [44], we feel we are on the threshold
of a new era in AD therapy in which therapies will slow
the rate of disease progression. Even for those who still
believe that the aim of therapy should be to reduce the
pathologic end result that characterizes the disease, the
hormone leptin shows promise in reducing extracellular
Ab, and the use of covalently conjugated nanoparticles
with iron chelators to solubilize Ab may overcome the
limitations of chelation therapy posed by the BBB.
Leuprolide therapy, and especially its temporal relation-
ship to menopause, may prove to be the treatment of
choice in preventing AD in women. Most of all, the
relationship between vascular and cognitive health and
the role played by the presence of glucose intolerance on
first one and then the other are yielding a new and
exciting approach to AD therapy, which may be
mechanistically based in oxidative stress. With improved
understanding of AD pathogenesis, there is little doubt
that the focus of AD therapy will shift to target what
appears to be a key player in disease evolution, namely
oxidative stress. In this respect, promising compounds
like dimebon warrant further development.
We have come a long way in our treatment strategies for
AD. Acknowledging that it is the molecular mechanisms
instrumental in the evolution of the disease, not the final
pathologic result [45], that should be the target is a very
big step in a promising direction. This is a very exciting
time for the field of Alzheimer’s research and should
prove fruitful.
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